Spero Therapeutics (NASDAQ: SPRO) — Perfil da empresa, notícias e dados financeiros
Spero Therapeutics develops treatments for multi-drug resistant bacterial infections, targeting antibiotic development for public health.

Spero Therapeutics
Spero Therapeutics (NASDAQ:SPRO) focuses on developing treatments for multi-drug resistant bacterial infections. With a robust pipeline primarily targeting the most critical and hard-to-treat bacterial infections, Spero is committed to innovating within the field of antibiotic development. The company's projects span across various stages of clinical development, aiming to address the growing global threat of antimicrobial resistance. One of their key objectives includes advancing their lead candidates through clinical trials to bring novel therapies to patients in need, while also exploring potential in antibacterial and diagnostic products to broaden their impact on public health. Spero Therapeutics is driven by a mission to save lives by revitalizing the arsenal against bacterial infections.
Resumo
Operações
Produtos e/ou serviços de Spero Therapeutics
- "SPR206, an IV-administered agent aimed at combating multidrug-resistant Gram-negative bacteria"
- "SPR720, an oral therapy for non-tuberculous mycobacterial (NTM) infections"
- "Potentiator platform, enhancing the performance of existing antibiotics against resistant bacteria"
- "SPR994, an oral formulation of tebipenem, targeting complicated urinary tract infections (cUTI)"
- "Collaborations with government and industry partners to develop and commercialize novel antimicrobial agents"
equipe executiva do Spero Therapeutics
- Esther P. RajaveluCEO, President, CFO, Chief Business Officer, Treasurer & Director
- Timothy KeutzerChief Operating Officer
- John RaymondSenior Vice President of Finance & Business Operations
- Debra Jeske ZackChief Medical Officer
- Sheila FinanSenior VP & Controller
Últimas notícias sobre a Spero Therapeutics
Principais indicadores financeiros
Resultados divulgados pela Spero Therapeutics, em USD.
- Cap. de mercado
- 68,1 mi
- Receita (TTM)
- 47 mi
- P/L
- 8.4
- LPA (diluído, TTM)
- 0.1
- Dividend yield
- —
- Margem de lucro
- 15.7%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 59,6 mi | -24 mil | 8,6 mi | |
| 48 mi | -73,4 mi | -68,6 mi | |
| 103,8 mi | 21,5 mi | 22,8 mi | |
| 48,6 mi | -42,2 mi | -46,4 mi |